-
Apr 16, 2026, 7:25 am96 pts
The Next Web
STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by existing investors including Pfizer Ventures and M Ventures. STORM Therapeutics, a Cambridge-based clinical-stage…
Trending Today on Tech News Tube
Tech News Tube is a real time news feed of the latest technology news headlines.
Follow all of the top tech sites in one place, on the web or your mobile device.
Follow all of the top tech sites in one place, on the web or your mobile device.
